You are here

Article Text

Article menu
Download PDFPDF
Original Articles
Efficacy of Lidocaine or Bupivacaine Combined With Ephedrine in Rat Sciatic Nerve Block
  1. Yi-Chuan Kau, M.D.,
  2. Yu-Chun Hung, M.D.,
  3. Anthony M. Zizza, B.A.,
  4. David Zurakowski, Ph.D.,
  5. William R. Greco, Ph.D., M.B.A.,
  6. Ging Kuo Wang, Ph.D. and
  7. Peter Gerner, M.D.
  1. From the Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
  2. Mackay Memorial Hospital, Taipei, Taiwan
  3. Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
  4. Department of Orthopaedic Surgery, Children's Hospital and Harvard Medical School, Boston, MA
  5. Cancer Prevention & Population Sciences, Roswell Park Cancer Institute, Buffalo, NY
  1. Reprint requests: Peter Gerner, M.D., Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail: pgerner{at}partners.org

Abstract

The adrenergic drug ephedrine inhibits Na+ current in cultured cells expressing Na+ channels and provides dose-dependent reversible rat sciatic nerve blockade. The dosage required for peripheral nerve blockade in humans would cause unacceptable cardiovascular side effects. We therefore hypothesized that either lidocaine or bupivacaine would show synergy with ephedrine in a rat sciatic nerve block model, allowing a dose reduction and limiting side effects while improving efficacy.

Methods: Sciatic nerves of anesthetized rats were exposed by lateral incision of the thighs; 0.2 mL of different concentrations of the following drugs was injected subfascially: bupivacaine, lidocaine, and ephedrine alone and bupivacaine or lidocaine combined with ephedrine (n = 8 per group). After animals recovered from anesthesia, a blinded investigator evaluated motor blockade (push against a balance) and sensory/nociceptive blockade (to pinch of the fifth toe) at predefined time intervals.

Results: Ephedrine combined with bupivacaine interacted additively for both motor and sensory blockade, and ephedrine combined with lidocaine interacted antagonistically (subadditive) for sensory blockade and additively for motor blockade.

Conclusions: A combination of ephedrine with either lidocaine or bupivacaine is unlikely to allow a significant dose reduction because of a lack of synergy. Furthermore, the cardiovascular side effects will limit the maximal tolerable dosage of ephedrine.

https://doi.org/10.1016/j.rapm.2005.08.008

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Supported by National Institutes of Health (research grant nos. GM64051 to PG and RR10742 to WRG, Bethesda, MD.) Lidocaine and bupivacaine were donated by AstraZeneca USA (Westborough, MA).

      Presented in part at the American Society of Regional Anesthesia and Pain Meeting in Toronto, Canada, April 21-24, 2005.